M.A.R.S. Clinical Trial Newsletters 2022, No. 1-6
|Title in English
|M.A.R.S. Clinical Trial Newsletters, 2022, No. 1-6
|Year of publication
|MU Faculty or unit
|MARS. is a randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of highly diluted atropine eye drops in slowing the progression of myopia in children, a phase IIIb, the three-parallel-arm study designed to increase clinical knowledge of the effect of topical application of highly diluted atropine on the growth of axial length in myopic eyes and supplementing experimental knowledge about the effectiveness and safety of this application. The Brno University Hospital initiated the study in cooperation with Masaryk University. This is a pediatric clinical evaluation, which will include a total of 288 patients in 5 centers in the Czech Republic.